Patient Engagement In Clinical Trials Needs More FDA Guidance, Stakeholders Say
Executive Summary
Industry urges US FDA guidance on developing plain language summaries, which could help improve the release of clinical trial results to patients.
You may also be interested in...
Clinical Trials: US FDA Should Frame Risk-Based Monitoring As Best Practice, ACRO Says
Recent Q&A draft guidance is aimed at assisting sponsors in planning and conducting risk-based approaches to monitoring, but ACRO’s Doug Peddicord says agency needs to take a more straightforward, proactive approach to encouraging the move away from 100% source data verification.
Pharma Requests Pilot To Test Public Value Of EU Guide On Plain Language Summaries
The European pharmaceutical trade group EFPIA says an “initial pilot” program should be launched to test the value and impact of the draft EU guideline on presenting lay summaries of clinical trial results. The group believes that the guideline should be reviewed following the pilot, as complying with it in its current form would result in companies shelling out “significant additional resources.”
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.